MilliporeSigma scales up lipid production for COVID-19 vaccines

By The Science Advisory Board staff writers

MilliporeSigma announced that it has launched a new high-purity synthetic cholesterol product to meet demand for lipids, a component of messenger RNA (mRNA)-based vaccines and therapeutics such as those used for COVID-19.

The launch of this new product follows the company's acquisition of AmpTec, a Hamburg, Germany-based mRNA contract development and manufacturing organization.

The company in February announced the extension of its strategic partnership with BioNTech to accelerate the supply of lipids and increase quantities to be delivered toward the end of 2021. The lipids will be used for the production of the Pfizer-BioNTech COVID-19 vaccine.

Filling of MilliporeSigma
Filling of MilliporeSigma's new synthetic cholesterol product at the company's Darmstadt, Germany facility. Image courtesy of MilliporeSigma.

Copyright © 2021

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?